Oppenheimer Increases Savara (NASDAQ:SVRA) Price Target to $15.00

Savara (NASDAQ:SVRA) had its target price hoisted by Oppenheimer from $11.00 to $15.00 in a research note released on Wednesday morning, Benzinga reports. The firm currently has an outperform rating on the stock.

A number of other analysts have also commented on the stock. JMP Securities reiterated a market outperform rating and issued a $8.00 price target on shares of Savara in a research note on Monday, May 6th. Piper Sandler boosted their target price on shares of Savara from $7.00 to $16.00 and gave the company an overweight rating in a research note on Monday, March 4th. Evercore ISI dropped their price target on Savara from $10.00 to $7.00 and set an outperform rating on the stock in a research note on Thursday, May 16th. Finally, HC Wainwright reiterated a buy rating and set a $6.00 price objective on shares of Savara in a research report on Monday, May 13th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of Buy and a consensus price target of $9.83.

Savara Stock Performance

SVRA stock opened at $3.84 on Wednesday. The stock has a market capitalization of $530.65 million, a PE ratio of -10.38 and a beta of 0.70. The stock’s 50 day simple moving average is $4.36 and its 200 day simple moving average is $4.64. Savara has a 12-month low of $2.60 and a 12-month high of $5.70. The company has a current ratio of 14.90, a quick ratio of 14.90 and a debt-to-equity ratio of 0.22.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). As a group, research analysts forecast that Savara will post -0.41 earnings per share for the current fiscal year.

Institutional Trading of Savara

Several hedge funds have recently bought and sold shares of SVRA. CANADA LIFE ASSURANCE Co purchased a new position in shares of Savara during the 1st quarter valued at about $35,000. AJOVista LLC purchased a new position in Savara during the fourth quarter valued at approximately $40,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Savara in the fourth quarter worth approximately $74,000. Tower Research Capital LLC TRC increased its stake in shares of Savara by 665.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 19,507 shares of the company’s stock worth $92,000 after purchasing an additional 16,959 shares in the last quarter. Finally, ProShare Advisors LLC raised its position in shares of Savara by 9.0% during the 1st quarter. ProShare Advisors LLC now owns 25,715 shares of the company’s stock valued at $128,000 after purchasing an additional 2,114 shares during the period. Institutional investors own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.